Literature DB >> 9311879

Neutralization sensitivity of cell culture-passaged simian immunodeficiency virus.

R E Means1, T Greenough, R C Desrosiers.   

Abstract

CEMx174- and C8166-45-based cell lines which contain a secreted alkaline phosphatase (SEAP) reporter gene under the control of a tat-responsive promoter derived from either SIVmac239 or HIV-1(NL4-3) were constructed. Basal levels of SEAP activity from these cell lines were low but were greatly stimulated upon transfection of tat expression plasmids. Infection of these cell lines with simian immunodeficiency virus (SIV) or human immunodeficiency virus type 1 (HIV-1) resulted in a dramatic increase in SEAP production within 48 to 72 h that directly correlated with the amount of infecting virus. When combined with chemiluminescent measurement of SEAP activity in the cell-free supernatant, these cells formed the basis of a rapid, sensitive, and quantitative assay for SIV and HIV infectivity and neutralization. Eight of eight primary isolates of HIV-1 that were tested induced readily measurable SEAP activity in this system. While serum neutralization of cloned SIVmac239 was difficult to detect with other assays, neutralization of SIVmac239 was readily detected at low titers with this new assay system. The neutralization sensitivities of two stocks of SIVmac251 with different cell culture passage histories were tested by using sera from SIV-infected monkeys. The primary stock of SIVmac251 had been passaged only twice through primary cultures of rhesus monkey peripheral blood mononuclear cells, while the laboratory-adapted stock had been extensively passaged through the MT4 immortalized T-cell line. The primary stock of SIVmac251 was much more resistant to neutralization by a battery of polyclonal sera from SIV-infected monkeys than was the laboratory-adapted virus. Thus, SIVmac appears to be similar to HIV-1 in that extensive laboratory passage through T-cell lines resulted in a virus that is much more sensitive to serum neutralization.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9311879      PMCID: PMC192146          DOI: 10.1128/JVI.71.10.7895-7902.1997

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  67 in total

1.  Evaluation of monoclonal antibodies to HIV-1 by neutralization and serological assays: an international collaboration. Collaborating Investigators.

Authors:  M P D'Souza; P Durda; C V Hanson; G Milman
Journal:  AIDS       Date:  1991-09       Impact factor: 4.177

2.  Hyperimmune antisera against synthetic peptides representing the glycoprotein of human immunodeficiency virus type 2 can mediate neutralization and antibody-dependent cytotoxic activity.

Authors:  E Björling; K Broliden; D Bernardi; G Utter; R Thorstensson; F Chiodi; E Norrby
Journal:  Proc Natl Acad Sci U S A       Date:  1991-07-15       Impact factor: 11.205

3.  Another discontinuous epitope on glycoprotein gp120 that is important in human immunodeficiency virus type 1 neutralization is identified by a monoclonal antibody.

Authors:  D D Ho; M S Fung; Y Z Cao; X L Li; C Sun; T W Chang; N C Sun
Journal:  Proc Natl Acad Sci U S A       Date:  1991-10-15       Impact factor: 11.205

4.  A predominant group-specific neutralizing epitope of human immunodeficiency virus type 1 maps to residues 342 to 511 of the envelope glycoprotein gp120.

Authors:  I Berkower; D Murphy; C C Smith; G E Smith
Journal:  J Virol       Date:  1991-11       Impact factor: 5.103

5.  Characterization of a discontinuous human immunodeficiency virus type 1 gp120 epitope recognized by a broadly reactive neutralizing human monoclonal antibody.

Authors:  M Thali; U Olshevsky; C Furman; D Gabuzda; M Posner; J Sodroski
Journal:  J Virol       Date:  1991-11       Impact factor: 5.103

6.  A capture enzyme immunoassay for detection of HIV-2/SIV antigen.

Authors:  R Thorstensson; L Walther; P Putkonen; J Albert; G Biberfeld
Journal:  J Acquir Immune Defic Syndr (1988)       Date:  1991

7.  Strain-specific neutralizing determinant in the transmembrane protein of simian immunodeficiency virus.

Authors:  T Kodama; D P Burns; D P Silva; F D Veronese; R C Desrosiers
Journal:  J Virol       Date:  1991-04       Impact factor: 5.103

8.  Vaccine protection by a triple deletion mutant of simian immunodeficiency virus.

Authors:  M S Wyand; K H Manson; M Garcia-Moll; D Montefiori; R C Desrosiers
Journal:  J Virol       Date:  1996-06       Impact factor: 5.103

9.  Inter- and intraclade neutralization of human immunodeficiency virus type 1: genetic clades do not correspond to neutralization serotypes but partially correspond to gp120 antigenic serotypes.

Authors:  J P Moore; Y Cao; J Leu; L Qin; B Korber; D D Ho
Journal:  J Virol       Date:  1996-01       Impact factor: 5.103

10.  A macaque adherent cell line that expresses human CD4 is susceptible to SIV: utility for assessing neutralizing antibody.

Authors:  S Goldstein; B Hague; D Montefiori; V M Hirsch
Journal:  J Virol Methods       Date:  1995-05       Impact factor: 2.014

View more
  92 in total

1.  Quintuple deglycosylation mutant of simian immunodeficiency virus SIVmac239 in rhesus macaques: robust primary replication, tightly contained chronic infection, and elicitation of potent immunity against the parental wild-type strain.

Authors:  K Mori; Y Yasutomi; S Ohgimoto; T Nakasone; S Takamura; T Shioda; Y Nagai
Journal:  J Virol       Date:  2001-05       Impact factor: 5.103

2.  Vaccine protection against simian immunodeficiency virus by recombinant strains of herpes simplex virus.

Authors:  C G Murphy; W T Lucas; R E Means; S Czajak; C L Hale; J D Lifson; A Kaur; R P Johnson; D M Knipe; R C Desrosiers
Journal:  J Virol       Date:  2000-09       Impact factor: 5.103

3.  Evidence against extracellular exposure of a highly immunogenic region in the C-terminal domain of the simian immunodeficiency virus gp41 transmembrane protein.

Authors:  Thomas S Postler; José M Martinez-Navio; Eloísa Yuste; Ronald C Desrosiers
Journal:  J Virol       Date:  2011-11-09       Impact factor: 5.103

4.  Association of structural changes in the V2 and V3 loops of the gp120 envelope glycoprotein with acquisition of neutralization resistance in a simian-human immunodeficiency virus passaged in vivo.

Authors:  Y Ye; Z H Si; J P Moore; J Sodroski
Journal:  J Virol       Date:  2000-12       Impact factor: 5.103

5.  Diversity and complexity of HIV-1 drug resistance: a bioinformatics approach to predicting phenotype from genotype.

Authors:  Niko Beerenwinkel; Barbara Schmidt; Hauke Walter; Rolf Kaiser; Thomas Lengauer; Daniel Hoffmann; Klaus Korn; Joachim Selbig
Journal:  Proc Natl Acad Sci U S A       Date:  2002-06-11       Impact factor: 11.205

6.  Modulation of Env content in virions of simian immunodeficiency virus: correlation with cell surface expression and virion infectivity.

Authors:  Eloísa Yuste; Jacqueline D Reeves; Robert W Doms; Ronald C Desrosiers
Journal:  J Virol       Date:  2004-07       Impact factor: 5.103

7.  Increased neutralization sensitivity of CD4-independent human immunodeficiency virus variants.

Authors:  P Kolchinsky; E Kiprilov; J Sodroski
Journal:  J Virol       Date:  2001-03       Impact factor: 5.103

8.  Recommendations for the design and use of standard virus panels to assess neutralizing antibody responses elicited by candidate human immunodeficiency virus type 1 vaccines.

Authors:  John R Mascola; Patricia D'Souza; Peter Gilbert; Beatrice H Hahn; Nancy L Haigwood; Lynn Morris; Christos J Petropoulos; Victoria R Polonis; Marcella Sarzotti; David C Montefiori
Journal:  J Virol       Date:  2005-08       Impact factor: 5.103

9.  Ability of herpes simplex virus vectors to boost immune responses to DNA vectors and to protect against challenge by simian immunodeficiency virus.

Authors:  Amitinder Kaur; Hannah B Sanford; Deirdre Garry; Sabine Lang; Sherry A Klumpp; Daisuke Watanabe; Roderick T Bronson; Jeffrey D Lifson; Margherita Rosati; George N Pavlakis; Barbara K Felber; David M Knipe; Ronald C Desrosiers
Journal:  Virology       Date:  2006-09-07       Impact factor: 3.616

10.  Derivation and characterization of a simian immunodeficiency virus SIVmac239 variant with tropism for CXCR4.

Authors:  Gregory Q Del Prete; Beth Haggarty; George J Leslie; Andrea P O Jordan; Josephine Romano; Nathaniel Wang; Jianbin Wang; Michael C Holmes; David C Montefiori; James A Hoxie
Journal:  J Virol       Date:  2009-07-15       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.